Home/Pipeline/Splenic Nerve Stimulation

Splenic Nerve Stimulation

Rheumatoid Arthritis

Phase 2Active

Key Facts

Indication

Rheumatoid Arthritis

Phase

Phase 2

Status

Active

Company

Galvani Bioelectronics

About Galvani Bioelectronics

Galvani Bioelectronics, founded in 2016, is a private joint venture between GSK and Verily Life Sciences (Alphabet) focused on developing precision bioelectronic therapies. Its core technology is an implantable, wirelessly controlled neuromodulation platform designed for minimally invasive delivery to treat chronic diseases, starting with immunomodulatory conditions like Rheumatoid Arthritis. The company is currently in the clinical development stage, enrolling patients for its lead RA program, and represents a convergence of biopharma and tech expertise in the emerging field of bioelectronics.

View full company profile

Therapeutic Areas

Rheumatoid Arthritis Autoimmune Diseases Immunology Chronic Inflammatory Diseases Neurological Disorders

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active